BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, Aso K, Hasegawa T, Aoshima M, Miyokawa N, Haneda M, Yoneda M. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006; 12(2): 322-326 [PMID: 16482638 DOI: 10.3748/wjg.v12.i2.322]
URL: https://www.wjgnet.com/1007-9327/full/v12/i2/322.htm
(0) (0) (5291) (85)
Number Citing Articles
1
Amal M.H. Mackawy, Mohammed E.H. Badawy, Ola Abd El-Rahman Yossef Megahed. Angiotensin converting enzyme (ACE D/I) polymorphism and its relation to liver fibrosis progression in Egyptian patients with chronic hepatitis C virus infection. Egyptian Journal of Medical Human Genetics 2012; 13(3) doi: 10.1016/j.ejmhg.2012.06.006
2
J.S. Lubel, F.J. Warner, P.W. Angus. Frontiers in Research of the Renin-Angiotensin System on Human Disease. 2007;  doi: 10.1007/978-1-4020-6372-5_6
3
Qiu-Zan Zhang, Ying-Li Liu, Yan-Rong Wang, Li-Na Fu, Jing Zhang, Xiu-Ru Wang, Bang-Mao Wang. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. Experimental and Therapeutic Medicine 2017; 14(3) doi: 10.3892/etm.2017.4809
4
A. Mantovani, G. Zoppini, G. Targher, G. Golia, E. Bonora. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. Journal of Endocrinological Investigation 2012; 35(2) doi: 10.1007/BF03345421
5
Brent A Neuschwander-Tetri. Fatty liver and the metabolic syndrome. Current Opinion in Gastroenterology 2007; 23(2) doi: 10.1097/MOG.0b013e32801421a9
6
Nicholas W.S. Chew, Mark D. Muthiah, Arun J. Sanyal. Cardiovascular Endocrinology and Metabolism. 2023;  doi: 10.1016/B978-0-323-99991-5.00003-6
7
Dawn M. Torres, Frances J. Jones, Janet C. Shaw, Christopher D. Williams, John A. Ward, Stephen A. Harrison. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial. Hepatology 2011; 54(5) doi: 10.1002/hep.24558
8
Dawn M. Torres, Stephen A. Harrison. Current treatments in nonalcoholic steatohepatitis. Current Treatment Options in Gastroenterology 2007; 10(6) doi: 10.1007/s11938-007-0042-y
9
James Neuberger. Zakim and Boyer's Hepatology. 2012;  doi: 10.1016/B978-1-4377-0881-3.00051-6
10
Erika Rabelo F Siqueira. A Review of Pharmacological Treatments of NASH. Gastroenterology & Hepatology: Open Access 2015; 2(5) doi: 10.15406/ghoa.2015.02.00058
11
Yuta Miyaoka, Denan Jin, Keitaro Tashiro, Shinsuke Masubuchi, Maiko Ozeki, Fumitoshi Hirokawa, Michihiro Hayashi, Shinji Takai, Kazuhisa Uchiyama. A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. Experimental Animals 2018; 67(2) doi: 10.1538/expanim.17-0126
12
Mariko Hojo, Sumio Watanabe. Pharmacological therapy of nonalcoholic steatohepatitis. Hepatology Research 2011; 41(3) doi: 10.1111/j.1872-034X.2011.00780.x
13
Thuy-Anh Le, Rohit Loomba. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. Journal of Clinical and Experimental Hepatology 2012; 2(2) doi: 10.1016/S0973-6883(12)60104-2
14
O. Guillaud, K.C. Gurram, M. Puglia, L. Lilly, O. Adeyi, E.L. Renner, N. Selzner. Angiotensin Blockade Does Not Affect Fibrosis Progression in Recurrent Hepatitis C After Liver Transplantation. Transplantation Proceedings 2013; 45(6) doi: 10.1016/j.transproceed.2013.01.067
15
Matthew J. Brookes, Tariq H. Iqbal, Brian T. Cooper. Hypertension and hepatic steatosis. Current Hypertension Reports 2008; 10(3) doi: 10.1007/s11906-008-0035-9
16
Palanivelu Praveenraj, Rachel M. Gomes, Saravana Kumar, Purushothaman Karthikeyan, Annapoorni Shankar, Ramakrishnan Parthasarathi, Palanisamy Senthilnathan, Subbiah Rajapandian, Chinnusamy Palanivelu. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery. Obesity Surgery 2015; 25(11) doi: 10.1007/s11695-015-1655-1
17
Nicholas W. S. Chew, Cheng Han Ng, Mark Dhinesh Muthiah, Arun J. Sanyal. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Current Atherosclerosis Reports 2022; 24(7) doi: 10.1007/s11883-022-01027-5
18
Luciana M. A. Borém, João F. R. Neto, Igor V. Brandi, Deborah F Lelis, Sergio H. S. Santos. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertension Research 2018; 41(6) doi: 10.1038/s41440-018-0040-6
19
Josephine A. Grace, Chandana B. Herath, Kai Yan Mak, Louise M. Burrell, Peter W. Angus. Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic options. Clinical Science 2012; 123(4) doi: 10.1042/CS20120030
20
Zhaoyang Ye, Houssam S. Hajj Houssein, Ram I. Mahato. Bioconjugation of Oligonucleotides for Treating Liver Fibrosis. Oligonucleotides 2007; 17(4) doi: 10.1089/oli.2007.0097
21
Stergios A. Polyzos, Jannis Kountouras, Christos Zavos, Eleni Tsiaousi. The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2010; 12(5) doi: 10.1111/j.1463-1326.2009.01176.x
22
Ahad Eshraghian. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World Journal of Gastroenterology 2017; 23(42): 7495-7504 doi: 10.3748/wjg.v23.i42.7495
23
Kenneth Cusi. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes & Obesity 2009; 16(2) doi: 10.1097/MED.0b013e3283293015
24
Phunchai Charatcharoenwitthaya, Jayant A. Talwalkar, Paul Angulo, Andrea A. Gossard, Jill C. Keach, Janice L. Petz, Roberta A. Jorgensen, Keith D. Lindor. Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid. Digestive Diseases and Sciences 2010; 55(2) doi: 10.1007/s10620-009-0744-1
25
Daniel R Pomaro, Francisco AH Fonseca, Anita LR Saldanha, Valeria P Lanzoni, Dulce E Casarini, Ana Paula Pantoja Margeotto, André LV , Tereza Luiza Bellincanta, Tania Leme da Rocha Martinez, Silvia SM Ihara. Diabetes and hypercholesterolemia experimental study on inhibition of liver fibrosis by angiotensin converting enzymes. Journal of Cardiology & Current Research 2021; 14(4) doi: 10.15406/jccr.2021.14.00524
26
Carolina M. Perdomo, Nuria Garcia-Fernandez, Javier Escalada. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?. Journal of Clinical Medicine 2021; 10(9) doi: 10.3390/jcm10092040
27
Eugen Florin Georgescu. Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option?. Advances in Therapy 2008; 25(11) doi: 10.1007/s12325-008-0110-2
28
Maria Soledad Rosselli, Adriana L. Burgueño, Julieta Carabelli, Mariano Schuman, Carlos J. Pirola, Silvia Sookoian. Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. Atherosclerosis 2009; 206(1) doi: 10.1016/j.atherosclerosis.2009.01.026
29
Yosui Tamaki, Yukiomi Nakade, Taeko Yamauchi, Yuichi Makino, Shiro Yokohama, Mitsuyoshi Okada, Kazunobu Aso, Hiroyuki Kanamori, Tomohiko Ohashi, Ken Sato, Haruhisa Nakao, Masakazu Haneda, Masashi Yoneda. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. Journal of Gastroenterology 2013; 48(4) doi: 10.1007/s00535-012-0651-7
30
Simone Moreira de Macêdo, Talita Antunes Guimarães, John David Feltenberger, Sérgio Henrique Sousa Santos. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides 2014; 62 doi: 10.1016/j.peptides.2014.10.005
31
Takeshi Okanoue, Atsushi Umemura, Kohichiroh Yasui, Yoshito Itoh. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. Journal of Gastroenterology and Hepatology 2011; 26(s1) doi: 10.1111/j.1440-1746.2010.06547.x
32
M Kamruzzman Munshi, Mohammad N Uddin, Shannon S Glaser. The role of the renin–angiotensin system in liver fibrosis. Experimental Biology and Medicine 2011; 236(5) doi: 10.1258/ebm.2011.010375
33
Ping Lu, Hailin Liu, Hang Yin, Liu Yang. Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cells. Medical Science Monitor 2011; 17(9) doi: 10.12659/MSM.881928
34
S. Kaser, C. F. Ebenbichler, H. Tilg. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. International Journal of Clinical Practice 2010; 64(7) doi: 10.1111/j.1742-1241.2009.02327.x
35
Shahinul Alam, Mushfiqul Abrar, Saiful Islam, Mohammad Kamal, Mohammad J Hasan, Md. Abdullah S Khan, Nooruddin Ahmad. Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial. JGH Open 2020; 4(4) doi: 10.1002/jgh3.12315
36
Claudia Della Corte, Anna Alisi, Raffaele Iorio, Arianna Alterio, Valerio Nobili. Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 2011; 12(12) doi: 10.1517/14656566.2011.587123
37
Mariana Machado, Helena Cortez-Pinto. Non-alcoholic steatohepatitis and metabolic syndrome. Current Opinion in Clinical Nutrition and Metabolic Care 2006; 9(5) doi: 10.1097/01.mco.0000241677.40170.17
38
Rafeeq Ali, Kenneth Cusi. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Annals of Medicine 2009; 41(4) doi: 10.1080/07853890802552437
39
Shivakumar Chitturi. Review: Treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology 2008; 1(3) doi: 10.1177/1756283X08096951
40
MH Ahmed, CD Byrne. Drug treatment and type 2 diabetes: the impact of liver disease. Practical Diabetes International 2007; 24(6) doi: 10.1002/pdi.1132
41
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano, Tooru Shimosegawa. Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology Research 2015; 45(4) doi: 10.1111/hepr.12511
42
Ki-Kwang Oh, Goo-Hyun Kwon, Kyeong Jin Lee, Jung-A Eom, Dong Joon Kim, Ki-Tae Suk. A roadmap to unveil the mechanism(s) of natural indole-derived molecules against NAFLD-derived HCC via systems pharmacology. Translational Oncology 2026; 63 doi: 10.1016/j.tranon.2025.102618
43
Bilal Hameed, Norah Terrault. Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2016; 20(2) doi: 10.1016/j.cld.2015.10.015
44
Fiona J. Warner, Harinda Rajapaksha, Nicholas Shackel, Chandana B. Herath. ACE2: from protection of liver disease to propagation of COVID-19. Clinical Science 2020; 134(23) doi: 10.1042/CS20201268
45
Vlad Ratziu, Maria Vispo, Mohamed Tahiri, Luminita Bonyhay, Mercedes de Torres, Carole Bernhardt, Thierry Poynard, Pascal Lebray. Peut-on traiter la stéatohépatite métabolique ?. Gastroentérologie Clinique et Biologique 2007; 31(3) doi: 10.1016/S0399-8320(07)89386-9
46
S. Strahl, K.P. Maier. Gibt es Therapieansätze für die nicht-alkoholische Fettleber und ihre Komplikationen?. Der Internist 2008; 49(12) doi: 10.1007/s00108-008-2151-7
47
Vlad Ratziu, Shira Zelber-Sagi. Pharmacologic Therapy of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009; 13(4) doi: 10.1016/j.cld.2009.07.001
48
Mark D. Muthiah, Ng Cheng Han, Arun J. Sanyal. A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know. Diabetes, Obesity and Metabolism 2022; 24(S2) doi: 10.1111/dom.14521
49
Jewel Imani, Steven P. M. Bodine, Anthony M. Lamattina, Diane D. Ma, Shikshya Shrestha, Dawn M. Maynard, Kevin Bishop, Arinze Nwokeji, May Christine V. Malicdan, Lauren C. Testa, Raman Sood, Benjamin Stump, Ivan O. Rosas, Mark A. Perrella, Robert Handin, Lisa R. Young, Bernadette R. Gochuico, Souheil El-Chemaly. Dysregulated myosin in Hermansky-Pudlak syndrome lung fibroblasts is associated with increased cell motility. Respiratory Research 2022; 23(1) doi: 10.1186/s12931-022-02083-w
50
Takumi Hirata, Kengo Tomita, Toshihide Kawai, Hirokazu Yokoyama, Akira Shimada, Masahiro Kikuchi, Hiroshi Hirose, Hirotoshi Ebinuma, Junichiro Irie, Keisuke Ojiro, Yoichi Oikawa, Hidetsugu Saito, Hiroshi Itoh, Toshifumi Hibi. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). International Journal of Endocrinology 2013; 2013 doi: 10.1155/2013/587140
51
Fiona J. Warner, John S. Lubel, Geoffrey W. McCaughan, Peter W. Angus. Liver fibrosis: a balance of ACEs?. Clinical Science 2007; 113(3) doi: 10.1042/CS20070026
52
Keisuke Okamura, Tetsu Okuda, Yosuke Takamiya, Kazuyuki Shirai, Hidenori Urata. High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart and Vessels 2019; 34(9) doi: 10.1007/s00380-019-01391-4
53
Amanda Ribeiro dos Santos, Aline Dionizio, Mileni da Silva Fernandes, Marília Afonso Rabelo Buzalaf, Beatriz Pereira, Débora de Fátima Almeida Donanzam, Sergio Marrone Ribeiro, Anamaria Mello Miranda Paniago, Ricardo de Souza Cavalcante, Rinaldo Poncio Mendes, James Venturini, Angel Gonzalez. Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel. PLOS Neglected Tropical Diseases 2021; 15(8) doi: 10.1371/journal.pntd.0009714
54
Carlo Fabris, Carlo Smirne, Stefano Fangazio, Pierluigi Toniutto, Michela Burlone, Rosalba Minisini, Davide Bitetto, Edmondo Falleti, Andrea Cerutti, Mario Pirisi. Influence of angiotensin‐converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. Hepatology Research 2009; 39(8) doi: 10.1111/j.1872-034X.2009.00518.x
55
Marko Duvnjak, Neven Baršić, Vedran Tomašić, Ivan Lerotić. Genetic polymorphisms in non-alcoholic fatty liver disease: Clues to pathogenesis and disease progression. World Journal of Gastroenterology 2009; 15(48): 6023-6027 doi: 10.3748/wjg.15.6023
56
Mariana Verdelho Machado, Anna Mae Diehl. Zakim and Boyer's Hepatology. 2018;  doi: 10.1016/B978-0-323-37591-7.00025-2
57
Kwang Yong Shim, Young Woo Eom, Moon Young Kim, Seong Hee Kang, Soon Koo Baik. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. The Korean Journal of Internal Medicine 2018; 33(3) doi: 10.3904/kjim.2017.317
58
Yasuhiro Miyake, Kazuhide Yamamoto. Role of gut microbiota in liver diseases. Hepatology Research 2013; 43(2) doi: 10.1111/j.1872-034X.2012.01088.x
59
Ramesh P Thylur, Sanjit K Roy, Anju Shrivastava, Thomas A LaVeist, Sharmila Shankar, Rakesh K Srivastava. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma . JGH Open 2020; 4(3) doi: 10.1002/jgh3.12336
60
Jung Gyu Park, Jong Soo Mok, Young In Han, Tae Sub Park, Keon Wook Kang, Cheol Soo Choi, Hee Dong Park, Joonghoon Park. Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-40322-1
61
J. K. Dowman, M. J. Armstrong, J. W. Tomlinson, P. N. Newsome. Current therapeutic strategies in non‐alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011; 13(8) doi: 10.1111/j.1463-1326.2011.01403.x
62
Mohsen Arabi, Raheleh Alimoradzadeh, Alireza Makian, Seyed Javad Shariat Nabavi, Farshad Divsalar, Mitra Kazemi Jahromi. Non-alcoholic Steatohepatitis Diagnosis and Treatment Medical and Surgery, Based on Guideline Updates: A Mini Review. Journal of Health Reports and Technology 2022; 8(3) doi: 10.5812/jhrt-119454
63
Lindsey J. Reese, Diane S. Tider, Alicia C. Stivala, Dawn A. Fishbein. Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection. AIDS Research and Treatment 2012; 2012 doi: 10.1155/2012/978790
64
Toshiya Machida, Taku Obara, Makoto Miyazaki, Jun Inoue, Nariyasu Mano. Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. Annals of Hepatology 2022; 27(4) doi: 10.1016/j.aohep.2022.100699
65
NC McAvoy, A Lockman, PC Hayes. Non alcoholic fatty liver disease (NAFLD): an overview. Journal of the Royal College of Physicians of Edinburgh 2007; 37(1) doi: 10.1177/1478271520073701003
66
Ka-Kit Li, James Neuberger. Recurrent nonviral liver disease following liver transplantation. Expert Review of Gastroenterology & Hepatology 2009; 3(3) doi: 10.1586/egh.09.16
67
Grace Hui-Min Wu, Barbara J Boucher, Yueh-Hsia Chiu, Chao-Sheng Liao, Tony Hsiu-Hsi Chen. Impact of chewing betel-nut (Areca catechu) on liver cirrhosis and hepatocellular carcinoma: a population-based study from an area with a high prevalence of hepatitis B and C infections. Public Health Nutrition 2009; 12(1) doi: 10.1017/S1368980008002073
68
David van der Poorten, Jacob George. Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatology International 2007; 1(3) doi: 10.1007/s12072-007-9011-8
69
Michael Fuchs, Arun J. Sanyal. The Liver. 2009;  doi: 10.1002/9780470747919.ch45
70
Eugen Florin Georgescu, Reanina Ionescu, Mihaela Niculescu, Laurentiu Mogoanta, Liliana Vancica. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World Journal of Gastroenterology 2009; 15(8): 942-954 doi: 10.3748/wjg.15.942
71
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology 2013; 19(4) doi: 10.3350/cmh.2013.19.4.325
72
L. B. Lazebnik, S. V. Turkina. Non-alcoholic fatty liver disease and hypertension: a bidirectional, mutually aggravating relationship. Experimental and Clinical Gastroenterology 2024; (10) doi: 10.31146/1682-8658-ecg-230-10-62-70
73
John S Lubel, Chandana B Herath, Louise M Burrell, Peter W Angus. Liver disease and the renin–angiotensin system: Recent discoveries and clinical implications. Journal of Gastroenterology and Hepatology 2008; 23(9) doi: 10.1111/j.1440-1746.2008.05461.x
74
William Peverill, Lawrie Powell, Richard Skoien. Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation. International Journal of Molecular Sciences 2014; 15(5) doi: 10.3390/ijms15058591
75
Paul Manka, Amos Zeller, Wing-Kin Syn. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019; 79(9) doi: 10.1007/s40265-019-01126-9
76
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano, Tooru Shimosegawa. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Journal of Gastroenterology 2015; 50(4) doi: 10.1007/s00535-015-1050-7
77
John Richard, Ildiko Lingvay. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Review of Cardiovascular Therapy 2011; 9(3) doi: 10.1586/erc.11.15
78
S. Gitto, G. Vitale, E. Villa, P. Andreone. Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future. Gastroenterology Research and Practice 2015; 2015 doi: 10.1155/2015/732870
79
Diana Barb, Paola Portillo-Sanchez, Kenneth Cusi. Pharmacological management of nonalcoholic fatty liver disease. Metabolism 2016; 65(8) doi: 10.1016/j.metabol.2016.04.004
80
Barham K. Abu Dayyeh, May Yang, Jules L. Dienstag, Raymond T. Chung. The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort. Digestive Diseases and Sciences 2011; 56(2) doi: 10.1007/s10620-010-1507-8
81
T. T. Gordon-Walker, A. Pellicoro, J. P. Iredale. Liver under Constant Attack — From Fat to Viruses. 2009;  doi: 10.1007/978-90-481-2759-7_15
82
Dawn M. Torres, Stephen A. Harrison. Diagnosis and Therapy of Nonalcoholic Steatohepatitis. Gastroenterology 2008; 134(6) doi: 10.1053/j.gastro.2008.02.077
83
J. S. Lubel, C. B. Herath, E. Velkoska, D. J. Casley, L. M. Burrell, P. W. Angus. Angiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture research. Cytotechnology 2008; 58(3) doi: 10.1007/s10616-009-9185-0
84
Mariana Verdelho Machado, Helena Cortez-Pinto. Non-alcoholic fatty liver disease: What the clinician needs to know. World Journal of Gastroenterology 2014; 20(36): 12956-12980 doi: 10.3748/wjg.v20.i36.12956
85
Mariana Machado, Pedro Marques-Vidal, Helena Cortez-Pinto. Hepatic histology in obese patients undergoing bariatric surgery. Journal of Hepatology 2006; 45(4) doi: 10.1016/j.jhep.2006.06.013
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.